BGLC
BGLC
NASDAQ · Trading Companies & Distributors

Bionexus Gene Lab Corp

$1.30
-0.09 (-6.47%)
As of Sep 28, 10:46 PM ET ·
Financial Highlights (FY 2026)
Revenue
11.25M
Net Income
-4,520,383
Gross Margin
14.6%
Profit Margin
-40.2%
Rev Growth
-12.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 14.6% 14.6% 60.4% 60.4%
Operating Margin -39.9% -35.9% 8.4% 8.8%
Profit Margin -40.2% -38.2% 9.4% 7.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 11.25M 12.79M 1.58M 1.38M
Gross Profit 1.64M 1.87M 956.1K 835.6K
Operating Income -4,490,295 -4,597,048 133.2K 121.1K
Net Income -4,520,383 -4,627,852 149.1K 96.1K
Gross Margin 14.6% 14.6% 60.4% 60.4%
Operating Margin -39.9% -35.9% 8.4% 8.8%
Profit Margin -40.2% -38.2% 9.4% 7.0%
Rev Growth -12.1% -12.1% +23.5% +22.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 748.7K 864.2K
Total Equity — — 3.20M 3.19M
D/E Ratio — — 0.23 0.27
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,321,289 -4,669,803 198.9K 172.0K
Free Cash Flow — — 98.9K 88.8K